Astrazeneca plc recently provided details on the discovery of the potent, direct and selective NLPR3 inflammasome inhibitor AZD-4144 for the treatment of inflammatory diseases.

Chengdu Zeling Biomedical Technology Co. Ltd. has identified compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, and inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders.

Several recent Janssen Pharmaceutica NV patents describe new NLRP3 inflammasome inhibitors reported to be useful for the treatment of traumatic brain injury, multiple sclerosis, amyotrophic lateral sclerosis, dementia, Huntington’s, Parkinson’s, Alzheimer’s and motor neuron diseases.

Daiichi Sankyo Co. Ltd. has divulged compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation, major depression, multiple sclerosis, multiple system atrophy, schizophrenia, autoimmune disease, Alzheimer’s disease and Parkinson’s disease, among others.

Mwyngil Therapeutics Inc. has synthesized compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of arthritis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), osteoporosis, hypertension, inflammation, SARS-CoV-2 infection (COVID-19), autoimmune disease and Alzheimer’s disease, among others.

Takeda Pharmaceutical Co. Ltd. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of neonatal-onset multisystem inflammatory disease (NOMID/CINCA), Muckle-Wells syndrome, familial cold autoinflammatory syndrome, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis and prion disease.

Kodiak Sciences Inc. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of age-related macular degeneration, choroidal neovascularization, diabetic macular edema, dry eye, glaucoma, bacterial keratitis, retinitis and uveitis, among others.

A joint Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. patent details NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders.

Merck Sharp & Dohme LLC has identified compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune diseases, Alzheimer’s disease and Parkinson’s disease, among others.

Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of cardiovascular disorders.